Press release
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
Presentation underscores potential of several high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth
About this update from Incyte Corporation
[{"type":"text","content":"\n\nPresentation underscores potential of several high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth\n\n\n\nCompany announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura®) in adults with hidradenitis suppurativa (HS)\n\n\n\nOverview of early pipeline, including preliminary results from Phase 1 study of INCB123667 (CDK2i), will also be presented\n\n\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) will highlight growth opportunities and provide key updates across its investigational pipeline and commercial portfolio during a presentation today at 7:30 a.m. PT at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.\n\n\n“As we enter 2024, we see great promise in our portfolio and its potential to drive long-term growth fueled by our strong R&D engine and broad commercial footprint across Oncology and Inflammation & Autoimmunity,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “Today, we provide further clarity into several potential high-impact product launches anticipated by 2030. This includes both indication expansion opportunities and the advancement of novel medicines that could broaden our ability to positively affect patients’ lives.”\n\n\nNotably, Incyte announces that the primary endpoint was met in its randomized, placebo-controlled, Phase 2 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in adults with mild/moderate hidradenitis suppurative (HS). At Week 16, patients receiving ruxolitinib cream 1.5% twice daily (BID) had significantly greater decreases from baseline versus placebo in total abscess and inflammatory nodule (AN) count, the primary endpoint of the study. The overall safety profile of ruxolitinib cream is consistent with previous data, and no new safety signals were observed. The Phase 2 data will be submitted for presentation at an upcoming scientific meeting in 2024. A Phase 3 study is currently being evaluated.\n\n\nAdditionally, the Company will highlight progress across its Oncology pipeline and the research it is advancing in areas of high potential, including promising early clinical efficacy data for INCB123667, a potent and selective inhibitor of CDK2, demonstrating its potential use as monotherapy or combination therapy for late-stage cancer...